Secukinumab: clinical trials recruiting now
FDA drug label
- FDA-approved
- Yes. Secukinumab appears in the FDA drug-label database. Marketed as COSENTYX.
- Drug class
- Interleukin-17A Antagonist (FDA established pharmacologic class)
- Mechanism of action
- Interleukin-17A Antagonists (as stated on the FDA label)
FDA-approved use
COSENTYX is a human interleukin-17A antagonist indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. ( 1.1 ) active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. ( 1.2 ) active ankylosing spondylitis (AS) in adults and pediatric patients 12 years of age and older. ( 1.3 ) active non-radiographic axial spondyloarthritis (nr-axSpA) in adults with objective signs of inflammation. ( 1.4 ) active enthesitis-related arthritis (ERA) in pediatric patients 4 years of age and older. ( 1.5 ) moderate to severe hidradenitis suppurativa (HS) in adults and pediatric patients 12 years of age and older. ( 1.6 ) 1.1 Plaque Psoriasis COSENTYX ® is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults and pediatric patients 6 years and older who are candidates for systemic therapy or phototherapy. 1.2 Psoriatic Arthritis COSENTYX is indicated for the treatment of active psoriatic arthritis (PsA) in adults and pediatric patients 2 years of age and older. 1.3 Ankylosing Spondylitis COSENTYX is indicated for th…
Phase breakdown
Conditions being studied
Recruiting trials involving Secukinumab
- Evaluating the Role of IL-17 as an Orchestrator of Peripheral-central Cross Talk in Depressive Symptoms
- Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
- Regulatory Post-Marketing Surveillance in Hidradenitis Suppurativa, Pediatric Plaque Psoriasis and JIA Treated With Cosentyx®(Secukinumab) in Korea
Common questions
Is Secukinumab FDA-approved?
Yes, marketed as COSENTYX.
How many recruiting trials involve Secukinumab?
3 recruiting trials across 10 conditions.
Is this list of trials complete?
No. For the full record, search ClinicalTrials.gov.